Pressemitteilungen

externe Meldungen

03.09.2020

Labvantage-Biomax GmbH

Biomax Informatics integrates thousands of patents, provided by Sagacious IP, in its semantic search platform AILANI

Planegg, Germany, 3rd September, 2020 - Biomax Informatics, Planegg, Germany, and Sagacious IP, Gurugram, India, today announced the integration of information on several thousand patents related to Therapies and Diagnosis submitted by Sagacious IP for Biomax’ semantic search platform AILANI.

 

AILANI (Artificial Intelligence Language Interface) is a search platform especially designed for the research needs of the Life Sciences sector. In view of the current Coronavirus pandemic, Biomax recently made AILANI for COVID-19 (freely available at ailani.ai) to support the rapid and successful search for drugs and suitable vaccines against COVID-19 infections.

 

As a research assistant, AILANI for COVID-19 integrates and continuously mines Medline abstracts, public PubMedCentral full-text articles, COVID-19/SARS-COV-2 bioRxiv/medRxiv and COVID-19/SARS-COV-2 Elsevier articles. In collaboration with Sagacious IP , Biomax has now extended this information to include thousands of patents focusing on coronavirus therapies and diagnostics. More than 2,000 are available as full texts and can be searched for to retrieve intellectual property information regarding COVID-19 therapies. Chemical structure information has also been extracted and can also be searched for in this platform.

 

“With the integration of this patent search, we are responding to the great demand from research institutes and companies, which has come to us since we launched AILANI,” commented Dr. Angela Bauch, Assistant Director Product Management and main responsible for AILANI at Biomax Informatics AG.

 

Ram Tenneti, Executive Vice President, Sagacious IP, added: “We are very pleased to be able to make our patent research intelligence available to scientists around the world with the help of AILANI and thus make a valuable contribution in the field of COVID-19 research. Sagacious remains committed through its Covid-19 Research Assistance Program for the greater good.”

 

Newsletter

Anmeldung

Archiv